期刊文献+

不同厂家洛索洛芬钠片溶出度比较 被引量:2

Comparison of Dissolution of Loxoprofen Sodium Tablets from Different Manufacturers
原文传递
导出
摘要 目的比较5个厂家洛索洛芬钠片在4种溶出介质中的溶出曲线,以评价该药品的质量。方法采用桨法、转速50 r·min^-1、溶出介质900 mL进行体外溶出试验,分别考察不同厂家洛索洛芬钠片在盐酸溶液、pH 4.5醋酸盐缓冲液、水和pH 6.8磷酸盐缓冲液4种溶出介质中的体外溶出行为,测定溶出曲线并采用相似因子法与原研药进行比较分析。结果5个厂家洛索洛芬钠片在盐酸溶液中的溶出曲线基本一致,4个厂家的样品与原研药在水中的溶出曲线差异较大,2个厂家样品批间差异明显。结论仿制药厂家生产的药品与原研药存在质量差异,建议结合生物等效性试验改进处方及生产工艺,提高该药品质量。 OBJECTIVE To compare the dissolution profiles of loxoprofen sodium tablets from 5 manufacturers in 4 dissolution media to evaluate the quality of the drug.METHODS The dissolution test was carried out with paddle method in dissolution medium at a volume of 900 mL and the rotating speed was 50 r·min^-1.The dissolution profiles of loxoprofen sodium tablets from different manufacturers in the 4 dissolution mediums of hydrochloric acid solution,pH 4.5 acetate buffer solution,water and pH 6.8 phosphate buffer solution were determined,and the dissolution curves were compared with the innovator drug product by the similar factor method.RESULTS The dissolution profiles of loxoprofen sodium tablets from 5 pharmaceutical manufacturers in hydrochloric acid solution were similar.The dissolution curves of the samples from the 4 manufacturers and the original drug in the water were quite different.There were significant differences between the batches of the 2 manufacturers.CONCLUSION There are differences in the quality of the drugs produced by generic manufacturers and the original drugs.It is recommended to improve the prescription and production process in combination with bioequivalence tests to improve the quality of the drugs.
作者 章燕 曹琳 陈仲益 ZHANG Yan;CAO Lin;CHEN Zhongyi(Ningbo Institute for Drug Control,Ningbo 315048,China)
出处 《中国现代应用药学》 CAS CSCD 北大核心 2019年第20期2531-2534,共4页 Chinese Journal of Modern Applied Pharmacy
基金 2017年浙江省省级药品质量风险考核项目
关键词 洛索洛芬钠片 溶出度 溶出曲线 相似因子 loxoprofen sodium tablets dissolution dissolution curve similar factor
  • 相关文献

参考文献3

二级参考文献20

  • 1唐黎明,陈桂良.洛索洛芬钠片溶出度测定及体内外相关性评价[J].中国医药工业杂志,2006,37(8):550-552. 被引量:7
  • 2EMA. Guideline: Guideline on the Investigation of Bioequivalence [s]. 2010.
  • 3FDA. Draft Guidance for Industry: Bioavailability and Bioequiva- lence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System[ S]. 2015.
  • 4FDA. Guidance for Industry: Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System[ S]. 2000.
  • 5WHO. Guidance: General notes on Biopharmaceutics Classifica- tion System (BCS) -based biowaiver applications[ S ]. 2014.
  • 6WHO Technical Report Series. Annex 7 : Muhisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability[ S]. 2006.
  • 7ALISON B.Martindale[M].38th ed.London:Pharmaceutical Press,2014:83.
  • 8NAOKI Y,SHINTARO S,MASAAKI M,et al. Synthesis and biological evaluation of loxoprofen derivatives[J].Bioorg Med Chem,2011,19(11):3299.
  • 9PAN XT(潘学田).China Drug Reference(中国药品实用手册)[M].Beijing(北京):Petroleum Industry Press(石油工业出版社),2001:B240.
  • 10JP XVI [S].2011:1431.

共引文献26

同被引文献30

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部